Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BeliVeR a Phase II Trial of Belimumab in Combination with Rituximab/venetoclax in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia

NCT05069051 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT05069051
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05069051 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BeliVeR a Phase II Trial of Belimumab in Combination with Rituximab/venetoclax in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia
Lead sponsor
University Hospital Tuebingen
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 19, 2022
Completion date
July 14, 2027
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphoid leukemia in relapse